Choose Your Country or Region

Bisacodyl

Name: Bisacodyl
Brand: Selleck Chemicals
SKU: S4047
Rating: 5 (0 reviews)

Catalog No.S4047

For research use only.

Bisacodyl (INN) is a stimulant laxative drug that works directly on the colon to produce a bowel movement.

CAS No. 603-50-9

Purity & Quality Control

Related Compound Libraries

Related Other Products

Telaglenastat (CB-839)^New

Telaglenastat (CB-839) is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. CB-839(Telaglenastat) inudces autophagy and has antitumor activity. Phase 1.
Setanaxib (GKT137831)^New

Setanaxib (GKT137831, GKT831) is a potent, dual NADPH oxidase NOX1/NOX4 inhibitor with Ki of 110 nM and 140 nM, respectively. Treatment with GKT137831 suppresses reactive oxygen species (ROS) production. GKT137831 partly inhibits ferroptosis.
LB-100^New

LB-100 is a water soluble protein phosphatase 2A (PP2A) inhibitor with IC50s of 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells.
Puromycin (CL13900) 2HCl

Puromycin 2HCl (CL13900) is an aminonucleoside antibiotic, which acts as a protein synthesis inhibitor.
Cyclosporin A (NSC 290193)

Cyclosporin A (Cyclosporine A, Cyclosporine, Ciclosporin, CsA) is an immunosuppressive agent, binds to the cyclophilin and then inhibits calcineurin with IC50 of 7 nM in a cell-free assay, widely used in organ transplantation to prevent rejection.
Cyclophosphamide (NSC-26271) Monohydrate

Cyclophosphamide (NSC-26271, Cytoxan) Monohydrate is a nitrogen mustard alkylating agent, it attaches the alkyl group to the guanine base of DNA, shown to crosslink DNA, causing strand breakage and inducing mutations.
Ganciclovir (BW 759)

Ganciclovir (RS-21592, BW-759, 2'-Nor-2'-deoxyguanosine) is an antiviral drug for feline herpesvirus type-1 with IC50 of 5.2 μM in a cell-free assay.
Calcitriol (RO215535)

Calcitriol (RO215535, Topitriol, 1,25-Dihydroxyvitamin D3) is a nonselective vitamin D receptor activator/agonist(VDRA), exhibiting a 10-fold higher vitamin D receptor (VDR) binding affinity(IC50=0.4 nM) than the selective VDRA paricalcitol. Solutions are best fresh-prepared.
Ribavirin (ICN-1229)

Ribavirin (NSC-163039, ICN-1229, RTCA, Tribavirin), a synthetic guanosine analogue, possesses a broad spectrum of activity against DNA and RNA viruses.
N6-methyladenosine (m6A)

N6-methyladenosine (m6A, NSC-29409, 6-Methyladenosine, N-Methyladenosine) is a base modified analog of adenosine and is found as a minor nucleoside in natural RNAs.

Download Inhibitor Catalog

Biological Activity

Description	Bisacodyl (INN) is a stimulant laxative drug that works directly on the colon to produce a bowel movement.
In vitro	Bisacodyl (10 μg/mL) increases mRNA expression level of TNF-α, COX2 and PGE2 in Raw264.7 cells. ^[1]
In vivo	Bisacodyl (20 mg/kg) results in a decrease in AQP3 protein expression and increased mRNA expression level of TNF-α in the colon of rats. ^[1] Bisacodyl inhibits water absorption in rat jejunum, ileum, and colon, the degree of inhibition is linearly related to the logarithm of the bisacodyl concentration over the range of 0.05 mg to 2.0 mg per 100 mL. ^[2] Bisacodyl (10 mg/kg, intragastrically) induces a significant decrease in jejunal NOS activity in rats. Bisacodyl (10 mg/kg, intragastrically) increases the distance traveled by the marker in all time periods. ^[3] Bisacodyl (5.9 mg/kg) decreases significantly jejunal and colonic (Na + K) ATPase activity as compared to saline-treated rats. Bisacodyl (5.9 mg/kg) increases significantly jejunal and colonic PGE2 content and stimulates jejunal and colonic adenyl cyclase activity as compared to those in control rats without affecting cAMP content. ^[4] Bisacodyl (4.3 mg/kg) coupled with AOM increases the number of crypt per focus, but not the number of tumors in rats. Bisacodyl (43 mg/kg) significantly increases the number of crypt per focus and tumors in rats. ^[5]

Protocol (from reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	72 mg/mL (199.23 mM)
	Water	Insoluble
	Ethanol	Insoluble

Chemical Information

Molecular Weight	361.39
Formula	C₂₂H₁₉NO₄
CAS No.	603-50-9
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	CC(=O)OC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC(=O)C)C3=CC=CC=N3

Download Bisacodyl SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03279341	Completed	Drug: polyethylene glycol\|Drug: Bisacodyl\|Drug: Prucalopride	Chronic Constipation	University Hospital Gasthuisberg	December 3 2012	Phase 4
NCT01424228	Completed	Drug: placebo\|Drug: prucalopride	Constipation	Shire\|Takeda	April 6 2011	Phase 4
NCT01147926	Completed	Drug: Placebo\|Drug: Prucalopride	Male Subjects With Chronic Constipation	Shire\|Takeda	September 23 2010	Phase 3
NCT01116206	Completed	Drug: Prucalopride\|Drug: Placebo	Constipation	Johnson & Johnson Pharmaceutical Research & Development L.L.C.	May 2010	Phase 3

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):